Last reviewed · How we verify
NCT03619187
An Interventional Study to Evaluate the Effect of Ivabradine on Exercise Capacity in Heart Transplant Recipients
Phase 3 trial testing Ivabradine in Heart Transplantation, Elevated Resting Heart Rate. Withdrawn.
19 February 2020
Quick facts
| Lead sponsor | Amgen |
|---|---|
| Phase | Phase 3 |
| Status | Withdrawn |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | supportive care |
| Start date | 2 November 2018 |
| Primary completion | 19 February 2020 |
| Estimated completion | 19 February 2020 |
Drugs / interventions tested
- Ivabradine (IVABRADINE) — full drug profile →
Conditions studied
- Heart Transplantation, Elevated Resting Heart Rate — all drugs for Heart Transplantation, Elevated Resting Heart Rate →
Sponsor
Amgen — full company profile →
Who can join
Adults 18 to 70, any sex, with Heart Transplantation, Elevated Resting Heart Rate. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The hypothesis is that the treatment with ivabradine will increase pVO2 after 16 weeks of treatment compared to baseline in the heart transplant recipient population with elevated resting HR.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03619187
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Ivabradine
Trials testing the same drug.
- NCT07268170 — Heart Rate Control Before Cardiac Computed Tomography in Adults for the Evaluation of Coronary Artery Disease · Phase 2, PHASE3 · enrolling by invitation
- NCT06312891 — Value of Heart Rate Lowering Therapy in Acute Myocarditis · unknown
- NCT06305806 — RECOVER-AUTONOMIC: Platform Protocol, Appendix B (Ivabradine) · Phase 2 · completed
- NCT06670690 — Comparison Between Atenolol,Propnalol and Ivabradine · NA · completed
- NCT05481177 — Ivabradine for Long-Term Effects of COVID-19 With POTS Cohort · Phase 4 · unknown
Other Amgen trials
Trials by the same sponsor.
- NCT07223190 — A Study Evaluating Subcutaneous Versus Intravenous Blinatumomab in Newly Diagnosed Adults With B-cell Precursor Acute Ly · Phase 3 · not yet recruiting
- NCT07493512 — Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate Cancer · Phase 1 · not yet recruiting
- NCT07531095 — Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC) · Phase 1 · not yet recruiting
- NCT06987539 — A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Gen · Phase 2 · recruiting
- NCT05909761 — Observational Safety Study in Women With Neuromyelitis Optica Spectrum Disorder (NMOSD) Exposed to UPLIZNA® During Pregn · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03619187 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Amgen
- Last refreshed: 19 November 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03619187.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing